G. Rosano, J. Tamargo, K. Kjeldsen, M. Lainščak, S. Agewall, S. Anker, C. Ceconi, A. Coats, H. Drexel, G. Filippatos, J. Kaski, L. Lund, A. Niessner, P. Ponikowski, G. Savarese, T. Schmidt, P. Seferovic, S. Wassmann, T. Walther, B. Lewis
2018.7.1European Heart Journal-Cardiovascular Pharmacotherapy
tlooto Summary
Patients with chronic kidney disease and HF are at increased risk of hyperkalaemia and ∼50% of these patients experience two or more yearly recurrences, so RAASi therapy should be down-titrated or more often discontinued even after a single episode of elevated potassium (K+) level.
Abstract
Abstract is not available.
Citation format
ROSANO, G., et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the working group on cardiovascular pharmacotherapy of the European society of cardiology. European Heart Journal-Cardiovascular Pharmacotherapy, 2018, 4: 180–188.